TP53 and breast cancer: In addition, targeting either HDAC3 or HDAC6 could also decrease the expression of survivin and increased the conversion of LC3-B-II in mutant p53-expressing SK-BR-3 breast cancer cells, further supporting the role of HDAC3 and HDAC6 in regulating survivin expression in the SAHA treated breast cancer cells regardless to the p53 status (Supplementary Figure 3).